J Musculoskelet Neuronal Interact 2(3):291–295PubMed 20. Bliziotes M et al (2006) Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 39(6):1313–1321PubMedCrossRef 21. Bliziotes MM et al (2001) Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29(5):477–486PubMedCrossRef 22. Westbroek I et al (2001) Expression of serotonin receptors in bone. J Biol Chem 276(31):28961–28968PubMedCrossRef 23. Gustafsson BI et al (2006)
Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98(1):139–151PubMedCrossRef 24. Vestergaard P et al (2008) Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int #www.selleckchem.com/products/th-302.html randurls[1|1|,|CHEM1|]# 82:92–101PubMedCrossRef 25. Herings R (1993) The PHARMO Drug Data Base: design and structure. PHARMO, a record linkage system for post-marketing Selleck Ruxolitinib surveillance of prescription drugs in The Netherlands. Doctoral thesis, Utrecht University, Utrecht, The Netherlands, pp 17–32 26. Buurma H, De
Smet PA, Egberts AC (2006) Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. Drug Saf 29(8):723–732PubMedCrossRef 27. Van der Schee E, Groenewegen PP, Friele RD (2006) Public trust in health care: a performance indicator? J Health Organ Manag 20(5):468–476PubMedCrossRef 28. Van Staa TP et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15(6):993–1000PubMedCrossRef 29. Herings RM et al (1996) Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 49(1):115–119PubMedCrossRef 30. Heerdink ER et al (1998) NSAIDs associated with increased risk
of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 158(10):1108–1112PubMedCrossRef 31. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health (2002) ATC classification index with DDDs 2002. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, Nydalen 32. Baldessarini R (2001) Drugs and the treatment of psychiatric disorders. Depression and anxiety disorders. Chapter 19, in Goodman & Gilman’s. In: Hardman J, Limbird L, Goodman A (eds) The pharmacological basis of therapeutics. SB-3CT McGraw-Hill, New York, p 456 33. Cherin P et al (1997) Risk of syncope in the elderly and consumption of drugs: a case–control study. J Clin Epidemiol 50(3):313–320PubMedCrossRef 34. Laursen AL et al (1985) Paroxetine in the treatment of depression—a randomized comparison with amitriptyline. Acta Psychiatr Scand 71(3):249–255PubMedCrossRef 35. Ensrud KE et al (2006) Use of selective serotonin reuptake inhibitors and sleep disturbances in community-dwelling older women. J Am Geriatr Soc 54(10):1508–1515PubMedCrossRef 36. Newman AB et al (1997) Sleep disturbance, psychosocial correlates, and cardiovascular disease in 5201 older adults: the Cardiovascular Health Study.
Related posts:
- A full description of this capacity to interact with another euka
- This line of inquiry has an interesting
history In 1993 - 64 The layer-specific changes in neuronal density and size ident
- Consistent with the Fos data, D-AP5 in the DMS, but not in the DL
- However, the mechanism by which mTORC2 is activated upon interact